Tom Reeves, President & CEO, will be focusing on Epidel, IBI’s local drug delivery technology, in his presentation. Epidel is a novel non-polymeric small molecule prodrug delivery platform which provides for controlled local drug delivery via surface erosion. The Epidel materials have polymer like properties which allow them to be made into standalone implants of various form factors with highly engineerable release kinetics.
“We’re excited to be presenting our proposed spin-out of our novel drug technology business at the Bloom Burton conference,” commented Reeves. “We want to capitalize on the commercial success of our Endexo anti-thrombogenic additives business and will be introducing our Epidel technology at the conference. We’ll also be providing data on our lead program (IBE-814) which is an intravitreal dexamethasone implant targeting major retinopathies including diabetic macular edema, retinal vein occlusion and non-infectious uveitis which we expect to enter Phase 2 clinical trials in 2020.”
About Interface Biologics, Inc. Interface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification additives are used in FDA-approved medical devices and are clinically proven to reduce infection and thrombus-related complications. IBI’s sustained local drug delivery technology is applicable across a range of drug classes and medical specialties with an initial focus on ophthalmology. www.interfacebiologics.com
About the Conference: The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.:
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
Media Contact: Julie Fotheringham, Partner, Hageman Communications M: 416-951-7988 E: Julie.firstname.lastname@example.org